TREE NEWS reports: Akeso’s shares dropped more than 24% after the company’s first US marketing application for its oncology immunotherapy drug ivonescimab was not approved. The rejection marks a setback for the Chinese biotech’s lead immuno-oncology candidate in the US market.
Akeso Falls Over 24% After Ivonescimab’s First US Marketing Application Rejected
The size of the share reaction reflects how much of Akeso's equity story had been tied to US market entry for its lead immuno-oncology asset, not just to domestic sales. A first marketing application rejection for a Chinese biotech's flagship candidate also lands in a sector where US regulatory clearance has become a key differentiator for valuation. Whether Akeso discloses the specific grounds for the rejection, and how quickly a refiling path becomes visible, is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.